Navigation Links
Pacemaker implantation for heart failure does not benefit nearly half of the patients

A new meta-analysis study, led by physician researchers at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine, and to be published in the Archives of Internal Medicine (embargoed until June 13, 4 p.m. EDT), shows that three-lead cardiac pacemakers implanted in those with heart failure fail to help up to 40 percent of patients with such devices.

"These findings have significant clinical implications and impact tens of thousands of patients in the U.S.," said Ilke Sipahi, MD, Associate Director of Heart Failure and Transplantation at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. "In this in-depth analysis, we found that pacemaker patients with less severe electrical disturbance in their hearts did not receive any benefit whatsoever from these expensive and potentially risky implants. Given the abundance of data showing lack of efficacy in this patient population, current treatment guidelines should be changed."

Dr. Sipahi, along with James Fang, MD, Director, Clinical Cardiovascular Services at UH Case Medical Center and Professor at Case Western Reserve University School of Medicine, investigated the treatment method known as cardiac resynchronization therapy (CRT). This highly sophisticated treatment technique involves pacing both ventricles of the heart in an attempt to correct the impaired synchrony during contraction of the heart.

Sometimes also referred to as "biventricular pacing," CRT is a form of therapy for congestive heart failure that utilizes a special pacemaker to re-coordinate the action of the heart chambers.

The study is a combined analysis of clinical trials of nearly 6,000 patients and examines whether the current criteria used by the medical community in selecting patients for the treatment are appropriate.

Treatment guidelines endorsed by various professional societies recommend these pacemakers for patients with heart failure symptoms due to weak heart muscles that have a specific abnormality on the electrocardiogram (EKG) known as QRS prolongation. Current treatment guidelines recommend that heart failure patients with QRS prolongation to greater than 0.12 seconds should get these devices.

However, the new meta-analysis demonstrates that patients do not have a survival benefit or a reduction in hospitalizations from these pacemakers, unless their QRS is prolonged to greater than 0.15 seconds, a threshold much greater than the 0.12 second cutoff advocated in the treatment guidelines. Approximately 40 percent of patients receiving these devices have a QRS prolongation in the range of 0.12 to 0.15 seconds and do not get any benefit from pacemaker therapy according to the results of the new study.

"This study can have profound impact on minimizing unnecessary procedures" added Dr. Sipahi. "Revising the criteria for implantation of these devices will help avoid thousands of unnecessary implants and will also lead to cutting down on unwarranted costs."

In contrast, the tandem's research also confirmed that patients with QRS prolongation greater 0.15 seconds got substantial benefit from their devices, lived longer and were hospitalized less often.

Heart failure, especially at its advanced stages, is a deadly disease affecting approximately 6 million Americans. Annual costs related to heart failure approached $40 billion in 2010. The global CRT devices market is expected to reach at $2.8 billion by 2015 with the North American segment accounting for nearly 40 percent of the global value.

"Our analysis suggests that this important therapy appears to benefit primarily those patients with the greatest prolongation in the QRS duration," said Fang. "This study may help to better select patients who are most likely to benefit from this effective but costly procedure."


Contact: Mike Ferrari
University Hospitals Case Medical Center

Related medicine news :

1. Keep MP3 Headphones 2 Centimeters or More From Pacemaker: Study
2. Could Stomach Pacemaker Be New Weight-Loss Tool?
3. FDA Approves First Pacemaker Deemed Safe During MRIs
4. Brain pacemakers: A long-lasting solution in the fight against depression
5. Pacemakers May Help Predict Strokes
6. Recycling pacemakers may alleviate burden of heart disease across the globe
7. Studies show everolimus-eluting stent implantation reduces restenosis and repeat revasculariztion
8. Ear Tubes Appear to Be Safe Before Cochlear Implantation
9. Medical Groups Update Heart, Blood Pressure Care Guidelines
10. 1 in 5 heart-attack deaths could be prevented with new drug
11. Heart Attack Victims Face Greater Risk of Dying When Ambulances Are Diverted
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Los Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... advanced da Vinci surgical robot is being more and more widely heralded as a ... robotic assisted da Vinci method has over traditional laparoscopic surgery is that it can ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: